CNBC Television
@CNBCtelevision·3.4M subscribers·157.5K videos
Former Aimmune Therapeutics CEO: Taking Stock in Allergies | Mad Money
Posted
June 22, 2018
Views
2,947
Likes
15
Comments
1
Engagement
June 22, 2018
2,947
15
1
0.54%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
5:55Now PlayingRoughly 15 million Americans have food allergies, including 5.9 million children under age 18. Jim Cramer talks to the recently retired CEO of Aimmune Therapeutics, a company hoping to help find a solution.
» Subscribe to CNBC
» Watch more Mad Money here
» Read more about Aimmune here
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news
Watch full episodes
Follow Mad Money on Twitter
Like Mad Money on Facebook
Follow Cramer on Twitter
Connect with CNBC News Online!
Visit CNBC.com
Find CNBC News on Facebook
Follow CNBC News on Twitter
Follow CNBC News on Google+
Follow CNBC News on Instagram
Former Aimmune Therapeutics CEO: Taking Stock in Allergies | Mad Money | CNBC
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
